Compare CAPR & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | CHCO |
|---|---|---|
| Founded | 2005 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2011 | 1995 |
| Metric | CAPR | CHCO |
|---|---|---|
| Price | $26.10 | $133.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | $44.63 | ★ $132.50 |
| AVG Volume (30 Days) | ★ 937.2K | 106.0K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | N/A | ★ 13.18 |
| EPS | N/A | ★ 2.20 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.16 |
| Revenue Next Year | $3.31 | $3.12 |
| P/E Ratio | ★ N/A | $60.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $113.21 |
| 52 Week High | $40.37 | $133.59 |
| Indicator | CAPR | CHCO |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 68.39 |
| Support Level | $25.48 | $120.29 |
| Resistance Level | $30.21 | N/A |
| Average True Range (ATR) | 1.40 | 2.79 |
| MACD | 0.33 | 0.47 |
| Stochastic Oscillator | 22.85 | 88.69 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.